Shares of EpiPen maker Mylan (NASDAQ: MYL) are down over 30% year-to-date amid media and regulatory scrutiny, and consumer backlash against repeated sharp price increases for the product. Pressure on the company, its management, and the stock price seem destined to continue for the foreseeable future. …read more
Read more here: Investors Find More Reasons to Dump Mylan Stock
Category: MYL, WFC
